MSIBIS-0002USC2 Serial No.: 10/608,354

REMARKS

Upon entry of the present amendment, claims 38-39, 95, 97-99, 101, 103, 104, 109-112, and 115-120 will be pending. Claims 113 and 114 are cancelled without prejudice or disclaimer. Claims 38-39, 95, 97-99, 101, 103, 104, 109-112 have been amended to more clearly describe the present invention. New claims 115-120 have been added. Claims 38-39, 95, 97-99, 101, 103, 104, 109-112 as amended and new claims 115-120 are fully supported by the specification as originally filed, including the working Examples and original claims. Accordingly, no new matter is added.

Interview

Applicants thank the Examiner for the helpful discussion with applicants' representative during the interview at the Patent Office on November 19, 2009.

Objection to the Specification

The Examiner objected to the amendment made to the specification in the Submission Filed with A Request for Continued Prosecution Under 37 C.F.R. § 1.114, filed July 1, 2009. In that submission, Applicants made clarifying changes to the incorporation by reference statements appearing in the first paragraph of the specification. The Examiner objected, remarking that the "original filed specification only describes incorporation of case 09/076,206," and not two additional patents listed in the paragraph. Office Action at page 2. The Examiner is mistaken. Applicants point out that page 2 of the Patent Application Transmittal Letter filed with the instant application included an amendment to the first paragraph of the specification. That amendment references the additional applications and patents objected to by the Examiner. Applicants respectfully request withdrawal of the objection to the amendments made to the specification.

Rejections under 35 U.S.C. § 112

The Examiner rejected claims 38-39, 95, 97-99, 101, 103, 104, and 109-114 under 35 U.S.C. § as allegedly indefinite. Without acquiescing to the rejection, claims 38-39, 95, 97-99, 101, 103, 104, 109-112 have been amended to more clearly describe the claimed invention. Applicants request reconsideration and withdrawal of the rejection of claims 38-39, 95, 97-99,

MSIBIS-0002USC2 Serial No.: 10/608,354

101, 103, 104, 109-112. Claims 113 and 114 have been cancelled. Accordingly, the rejection is most with respect to those claims.

CONCLUSION

Applicants believe that all outstanding issues in this case have been resolved and that the present claims are in condition for allowance. Nevertheless, if any undeveloped issues remain or if any issues require clarification, the Examiner is invited to contact the undersigned at the telephone number provided below in order to expedite the resolution of such issues.

FEES

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 50-0252 referencing docket no. MSIBIS-0002USC2.

Respectfully submitted

Dated: 24 Feb 2010

By:

Jason D. Ferrone

Registration No. 52,887 Customer No. 27,180

Isis Pharmaceuticals, Inc 1896 Rutherford Rd. Carlsbad, CA 92008 (760) 603-2710 – Phone (760) 603-3820 – Facsimile